Trial · NCT07892807
The Mindful Smartphone Use Study
NCT07892807, Not applicable, Recruiting, Brown University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Mindful Smartphone Use Study. Trials, record NCT07892807. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892807
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Mindful Smartphone Use Study
- NCT number
- NCT07892807
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Brown University
- Conditions
- Problematic Phone Use Behavior, Depression, Anxiety
- Interventions
- Mindwire
- First posted
- 2026-10-23
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Study Recruitment Feasibility as Measured by Participant Recruitment Rates | During recruitment period of study, up to 3 months | Participant recruitment will be assessed as the percentage (%) of eligible individuals who enroll in the study out of the total number of individuals screened for eligibility. This data will be collected using tracking sheets maintained by the research team, which document the number of individuals assessed for eligibility and those who subsequently consent and enroll. This recruitment rate will be used to evaluate the feasibility of the study/intervention. |
| Primary | Study Retention Feasibility as Measured by Participant Retention Rates | Baseline, Post-intervention (day 18), and 2-month Follow-up | Participant retention rates will be assessed as the percentage (%) of enrolled participants who complete study assessments at each time point (baseline, post-intervention, and 2-month follow-up). This will be data will be collected using assessment completion records maintained by the research team, which document participant completion of assessments. This retention rate will be used to evaluate the feasibility of the intervention. |
| Primary | Intervention Engagement Feasibility as Measured by Participant Engagement with Intervention | During intervention period (18 days) | Participant engagement with the intervention (i.e., adherence) will be assessed as the percentage (%) of prescribed intervention activities completed by participants over the study period. This data will be collected using application logs and session attendance records maintained by the research team. This engagement data will be used to evaluate the feasibility of the intervention. |
| Primary | Intervention Acceptability as Measured by Client Satisfaction Questionnaire (CSQ-8) | Post-intervention (day 18) | The validated 8-item Client Satisfaction Questionnaire (CSQ-8) will be used to measure the acceptability of the GEM intervention. Participants rate each item on a four-point Likert scale. Total scores for the CSQ-8 range from 8 to 32, with higher scores indicating higher satisfaction with the intervention. |
| Primary | Intervention Acceptability as Measured by Session Evaluation Form | Post-intervention (day 18) | Session evaluation form (a self-developed measure) will be used to measure the acceptability of the GEM intervention. The instrument consists of 10 questions, rated on a four-point Likert scale. Total scores range from 10 to 40, with higher scores indicating higher satisfaction with the intervention. |
| Secondary | Anxiety Symptoms as Measured by General Anxiety Disorder-7 (GAD-7) | Baseline, Post-intervention (day 18), and 2-month Follow-up | The validated General Anxiety Disorder-7 (GAD-7) scale will be used to measure participants' anxiety symptoms. Participants rate 7 statements on a four-point Likert scale. Total scores for GAD-7 range from 0 to 21, with higher scores indicating more severe levels of anxiety symptoms. |
| Secondary | Depression Symptoms as Measured by Center for Epidemiologic Studies Depression Scale (CES-D) | Baseline, Post-intervention (day 18), and 2-month Follow-up | The validated Center for Epidemiologic Studies Depression Scale (CES-D) scale will be used to measure participants' depression symptoms. Participants rate 20 statements on a four-point Likert scale. Total scores for CES-D range from 0 to 60, with higher scores indicating more severe levels of depression symptoms. |
| Secondary | Problematic Smartphone Use as Measured by Smartphone Addiction Scale - Short Version (SAS-SV) | Baseline, Post-intervention (day 18), and 2-month Follow-up | The validated Smartphone Addiction Scale - Short Version (SAS-SV) scale will be used to measure participants' problematic phone use behavior. Participants rate 10 statements on a six-point Likert scale. Total scores for CES-D range from 10 to 60, with higher scores indicating a greater degree of problematic smartphone use. |
| Secondary | Sleep Quality as Measured by Adolescent Sleep Quality Scale (ASQS) | Baseline, Post-intervention (day 18), and 2-month Follow-up | The validated Adolescent Sleep Quality Scale (ASQS) scale will be used to measure participants' sleep quality. Participants rate 8 statements on a four-point Likert scale. Total scores for CES-D range from 8 to 32, with higher scores indicating a worse sleep quality. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P20GM139743 | COBRE Center for Sleep and Circadian Rhythms in Child and Adolescent Mental Health | Carskadon, Mary A | EMMA PENDLETON BRADLEY HOSPITAL | NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES | 2021 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07892807
GET https://conductscience.org/api/trials/v1/NCT07892807/registered